Biotechnology

Biosion, Inc. Appoints Steven Knapp, Pharm.D. as Chief Regulatory & Quality Officer

NEWARK, Del. and NANJING, China, Aug. 22, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a leading global R&D biotechnology company, today announced the appointment ofSteven Knapp, PharmD., as Chief Regulatory & Quality Officer. In this position, he is responsible for the strategic leadership...

2022-08-22 13:00 1773

World's First CAR-T for NMOSD Treatment, IASO Biotherapeutics' Equecabtagene Autoleucel, Receives IND Approval by NMPA

SHANGHAI, NANJING, China and SAN JOSE, Calif., Aug. 19, 2022 /PRNewswire/ -- IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, announced today that the Center for Drug ...

2022-08-19 18:41 1970

J INTS BIO successfully held its 1st International Advisory Board Meeting for its Novel Oral 4th Generation EGFR TKI (JIN-A02) in Vienna, Austria during WCLC

SEOUL, South Korea, Aug. 19, 2022 /PRNewswire/ -- J INTS BIO announced that it held its 1st International Advisory Board Meeting for its Novel Oral 4th Generation EGFR-TKI 'JIN-A02' on the sideline of the 2022 IASLC World Conference on Lung Cancer held inVienna, Austria, on 7th August. This follo...

2022-08-19 16:00 1099

Nuance Pharma Announces Clearance of IND Application for Ensifentrine Pivotal Clinical Trials for COPD in China

SHANGHAI, Aug. 18, 2022 /PRNewswire/ -- Nuance Pharma ("the Company") announces the Center for Drug Evaluation ("CDE") has approved its Investigational New Drug ("IND") application supporting its pivotal clinical trial ofEnsifentrine for the maintenance treatment of chronic obstructive pulmonary ...

2022-08-19 11:24 1604

Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand for Adolescents Aged 12 Through 17

* Nuvaxovid™ is New Zealand's only protein-based COVID-19 vaccine GAITHERSBURG, Md., Aug. 18, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that New...

2022-08-18 21:06 2287

Case Report of Long Term Complete Response in Hepatocellular Carcinoma to CARsgen's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology

SHANGHAI, Aug. 18, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that a case report, titled "Long Term Complete Response of Advanced H...

2022-08-18 20:50 1850

Standigm names Carl Foster chief business officer to expand strategic partnerships for AI drug discovery

Veteran biotech and pharmaceutical executive will help company increase its growth and international impact SEOUL, South Korea, Aug. 18, 2022 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, toda...

2022-08-18 20:30 1793

WeTrade Group Inc. Ready to kick-off a Strategic Partnership with Zhixun Bio through WeTrade's SaaS platform and its the Internet of Things (IoT)

BEIJING, Aug. 18, 2022 /PRNewswire/ -- WeTrade Group Inc. ("WeTrade" or the "Company") (NASDAQ: WETG), an emerging growth company engaged in the business of providing software-as-a-services (SAAS) and cloud intelligent systems for micro-businesses, today announced the Company is in an advanced di...

2022-08-18 20:23 2216

Zylox-Tonbridge maintains strong revenue and gross profit growth, including gross margin improvement driven by its platform-based strategy in 1H22

HANGZHOU, China, Aug. 18, 2022 /PRNewswire/ -- On August 15, Zylox-Tonbridge (2190.HK, "the Company") released its 2022 interim results. The Company's revenue increased 113.7% YoY to RMB 1.53 billion in the first six months of 2022. The revenue of neurovascular interventional products business i...

2022-08-18 14:57 1753

WuXi Biologics Reports Strong 2022 Interim Results

Revenue Increased by 63.5% Y-o-Y to RMB7,206.4 Million Gross Profit Increased by 48.6% Y-o-Y to RMB3,413.2 Million Net Profit Grew by 39.2% Y-o-Y to RMB2,621.2 Million Adjusted Net Profit Rose by 60.9% to RMB2,914.9 Million Total Backlog Reached US$18,467 Million *       *        * Non-COVID Re...

2022-08-17 21:32 3545

Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand as a First and Second Booster for Adults

* Nuvaxovid™ is New Zealand's first and only protein-based COVID-19 vaccine * Nuvaxovid™ can now be used as a first or second booster dose for adults aged 18 and older vaccinated with any primary series vaccine GAITHERSBURG, Md., Aug. 17, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a bi...

2022-08-17 20:00 3217

WuXi STA Breaks Ground for New Pharmaceutical Manufacturing Facility in Middletown, Delaware

MIDDLETOWN, Del., Aug. 16, 2022 /PRNewswire/ -- WuXi STA, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to announce the groundbreaking for its new 190-acre pharmaceutical manufacturing campus inMiddletown, Delaware. First announced in June 2021, this...

2022-08-17 01:47 4495

J INTS BIO, Oral presentation of Preclinical results of its Novel Oral 4th Generation EGFR TKI 'JIN-A02' at the 2022 World Conference on Lung Cancer in Vienna, Austria (IASLC 2022 WCLC)

SEOUL, South Korea, Aug. 16, 2022 /PRNewswire/ -- J INTS BIO announced that the pre-clinical data of its novel, orally administered 4th generation EGFR TKI 'JIN-A02' was presented on the 8th of August, at the 2022 IASLC World Conference on Lung Cancer held inVienna, Austria, during the official s...

2022-08-16 13:35 1673

Bridge Biotherapeutics Receives FDA Authorization to Proceed with Phase 2 Study of BBT-877

* BBT-877 is intended to explore its treatment efficacy in idiopathic pulmonary fibrosis patients in a Phase II trial expected to start in 2022 SEONGNAM, South Korea, Aug. 15, 2022 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotechnology company developing ...

2022-08-16 08:17 1938

JIN-A02, A Novel 4th Generation EGFR TKI selected for the European Thoracic Oncology Platform - A First for Korean Pharma.

SEOUL, South Korea, Aug. 11, 2022 /PRNewswire/ -- J INTS BIO announced that the pre-clinical data of its novel, orally administered 4th generation EGFR TKI 'JIN-A02' was presented at the 2022 IASLC World Conference on Lung Cancer in Vienna, Austria on 8th August, at the official session "Overcomin...

2022-08-12 10:13 1787

WuXi ATU Announces Licensing Agreement with Janssen for TESSA™ Technology

PHILADELPHIA, Aug. 11, 2022 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced a licensing agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson ("Janssen"). Under this agreement, WuXi ATU ...

2022-08-12 09:09 2035

Panacell Biotech to conduct toxicity tests for NK cells, exosomes, and brown adipose-derived stem cells to treat patients with long COVID

SEOUL, South Korea, Aug. 10, 2022 /PRNewswire/ -- Panacell Biotech Co., Ltd. said that NK cells, exosomes, and brown adipose-derived stem cells are effective to treat patients with long COVID conditions, or post COVID-19 conditions, as well as those with terminal illness.

2022-08-10 22:00 2766

WeTrade Group Entered Into A Strategic Partnership With Jiqing, Acquiring Monkeypox Test Kits Exclusive Sales Channel

BEIJING, Aug. 10, 2022 /PRNewswire/ -- WeTrade Group Inc. ("WeTrade" or the "Company") (NASDAQ: WETG), an emerging growth company engaged in the business of providing software-as-a-services (SAAS) and cloud intelligent systems for micro-businesses, officially singed the strategic partnership agre...

2022-08-10 20:36 2329

Bridge Biotherapeutics Presents Promising Interim Clinical Study Results from Phase 1 Study of BBT-176 at WCLC 2022

* The study confirmed preliminary efficacy and safety of BBT-176 along with its treatment responses in advanced NSCLC patients * A patient with the C797S triple mutation showed up to 53 percent reduction in EGFR mutant allelic change VIENNA and SEONGNAM, South Korea, Aug. 9, 2022 /PRNewswire/...

2022-08-10 11:43 1753

iNtRON developed New CRISPR/Cas technology specific for Bacteriophage as PHAGERUS® Platform

* CRISPR/Cas system for bacteria that are not E. coli or Streptococcus pyogenes * Customized gene editing technology for unique modified-bacteriophages * To validate efficacy of SARS-CoV-2 mimotopes loaded PHAGERUS® platform BOSTON and SEOUL, South Korea, Aug. 9, 2022 /PRNewswire/ -- iNtRON ...

2022-08-10 09:00 1583
1 ... 72737475767778 ... 129

Week's Top Stories